Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle – A new strategy against peritoneal dissemination of gastric cancer
- 1 December 2008
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 272 (2) , 307-315
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 37 references indexed in Scilit:
- Reply: Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skinJournal of the European Academy of Dermatology and Venereology, 2006
- Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedsideCancer Treatment Reviews, 2006
- Neoadjuvant treatment of gastric cancer with peritoneal disseminationEuropean Journal of Surgical Oncology, 2006
- Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugarGastrointestinal Endoscopy, 2006
- Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancerCancer Letters, 2004
- Transduction of Soluble Flt-1 Gene to Peritoneal Mesothelial Cells Can Effectively Suppress Peritoneal Metastasis of Gastric CancerCancer Research, 2004
- Prolongation of epidural bupivacaine effects with hyaluronic acid in rabbitsInternational Journal of Pharmaceutics, 2004
- Ascites and the Plasma Concentration-Time Courses of the Taxanes Antitumor Agents Taxanes after an Intraperitoneal Administration in Patients with Peritoneal TumorsIryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2003
- Fluid Dynamics in Man of an Intraperitoneal Drug Delivery Solution: 4% IcodextrinDrug Delivery, 2001
- Pharmacologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodentsCancer, 1993